Ken Uchibori
YOU?
Author Swipe
View article: Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor
Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor Open
HNF4α expression in TTF-1-negative non-Sq NSCLC was associated with worse prognosis in patients treated with ICI.
View article: Impact of Immune-Related Adverse Event Severity on Overall Survival in Patients Receiving Immune Checkpoint Inhibitors Therapy, with a Focus on Combination Regimens
Impact of Immune-Related Adverse Event Severity on Overall Survival in Patients Receiving Immune Checkpoint Inhibitors Therapy, with a Focus on Combination Regimens Open
View article: Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer Open
Targeting the drug tolerant persister (DTP) state in cancer cells should prevent further development of resistance mechanisms. This study explored combination therapies to inhibit alectinib-induced DTP cell formation from anaplastic lympho…
View article: Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Open
Background: A prognostic marker in patients with non-small-cell lung cancer (NSCLC) treated with anti-PD-1/PD-L1 antibodies must be established. This study explored serum cytokeratin fraction 21–1 (CYFRA 21-1), which represents a squamous …
View article: Combined blockade of <scp>GPX4</scp> and activated <scp>EGFR</scp>/<scp>HER3</scp> bypass pathways inhibits the development of <scp>ALK</scp>‐inhibitor‐induced tolerant persister cells in <scp><i>ALK</i></scp>‐fusion‐positive lung cancer
Combined blockade of <span>GPX4</span> and activated <span>EGFR</span>/<span>HER3</span> bypass pathways inhibits the development of <span>ALK</span>‐inhibitor‐induced tolerant persister cells in <span><i>ALK</i></span>‐fusion‐positive lung cancer Open
Cancers can develop resistance to treatment with ALK tyrosine kinase inhibitors (ALK‐TKIs) via emergence of a subpopulation of drug‐tolerant persister (DTP) cells that can survive initial drug treatment long enough to acquire genetic aberr…
View article: Distinction of <scp><i>ALK</i></scp> fusion gene‐ and <scp><i>EGFR</i></scp> mutation‐positive lung cancer with tumor markers
Distinction of <span><i>ALK</i></span> fusion gene‐ and <span><i>EGFR</i></span> mutation‐positive lung cancer with tumor markers Open
Background It is difficult to predict gene mutations individually based on clinical background alone. Tumor markers may help to predict each gene mutation. Identifying tumor markers that can predict gene mutation will facilitate timely gen…
View article: An Exploratory Study of Specimen Processing Methods for Successful Multiplex Genetic Analyses Using Lung Surgical Specimens
An Exploratory Study of Specimen Processing Methods for Successful Multiplex Genetic Analyses Using Lung Surgical Specimens Open
目的.非小細胞肺癌の周術期治療は個別化に向かい,今後は手術症例でも,次世代シーケンサーを用いたマルチプレックス遺伝子検査が求められる.手術検体からマルチプレックス遺伝子検査を成功させるためには適切な検体処理が重要となる.そこで本研究では,当院の肺手術検体処理方法を検証し,手術検体からマルチプレックス遺伝子検査を成功させるための指標を得ることを目的とした.方法.手術予定の臨床病期IA3~IIIA期非小細胞肺癌30症例を前向きに検討した.各症例の迅速病理診断用検体を10%ホルマ…
View article: Efficacy of osimertinib in patients with <scp><i>EGFR</i></scp>‐mutation positive non‐small cell lung cancer with malignant pleural effusion
Efficacy of osimertinib in patients with <span><i>EGFR</i></span>‐mutation positive non‐small cell lung cancer with malignant pleural effusion Open
Background As an epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI), osimertinib has emerged as a standard EGFR ‐mutation positive treatment for non‐small cell lung cancer (NSCLC). However, the efficacy of osimertinib fo…
View article: Clinical characteristics of patients with <i>KRAS</i> mutation detected by liquid biopsy
Clinical characteristics of patients with <i>KRAS</i> mutation detected by liquid biopsy Open
Background KRAS mutation positive lung cancer is known to be clinically characterized by older age, males, and smokers. It is reported to be more common in mucinous adenocarcinoma, but all reports are based on analysis of tissue samples. R…
View article: Targeting ErbB and tankyrase1/2 prevent the emergence of drug tolerant persister cells in ALK fusion positive lung cancer
Targeting ErbB and tankyrase1/2 prevent the emergence of drug tolerant persister cells in ALK fusion positive lung cancer Open
Targeting the drug tolerant persister (DTP) state in cancer cells should prevent further development of resistance mechanisms. This study explored combination therapies to inhibit alectinib-induced DTP cell formation from anaplastic lympho…
View article: Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors Open
The survival of patients with NSCLC was improved from period D to period E, regardless of the presence of driver gene alteration. We found that next-generation TKIs and ICIs may be associated with improvements in overall survival.
View article: Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer
Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer Open
The Genexus™ Integrated Sequencer system is an automated, accurate NGS system with short turnaround time (TAT) that could assist clinicians to make more timely decision.
View article: A phase <scp>II</scp> feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (<scp>YLOG0114</scp>)
A phase <span>II</span> feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (<span>YLOG0114</span>) Open
Background A standard treatment regimen for advanced non‐small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) has not been established since most clinical trials exclude such patients because of the high risk of acu…
View article: Comparison of salvage surgeries for lung adenocarcinoma treated with anaplastic lymphoma kinase-tyrosine kinase inhibitors
Comparison of salvage surgeries for lung adenocarcinoma treated with anaplastic lymphoma kinase-tyrosine kinase inhibitors Open
View article: Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib Open
Background Most patients treated with anaplastic lymphoma kinase ( ALK ) ‐tyrosine kinase inhibitors for ALK ‐positive non‐small cell lung cancer (NSCLC) develop resistance, leading to metastasis, with progression to the central nervous sy…
View article: Impact of Renin–angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients
Impact of Renin–angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients Open
The use of RASi was associated with a significantly longer PFS in NSCLC patients treated with anti-PD-1/PD-L1 antibodies. RASi use may enhance the efficacy of anti-PD-1/PD-L1 antibodies.
View article: Clinical influence of switching companion diagnostic tests for <scp>EGFR‐TKs</scp> from <scp>Therascreen to Cobas v2</scp>
Clinical influence of switching companion diagnostic tests for <span>EGFR‐TKs</span> from <span>Therascreen to Cobas v2</span> Open
Background Several companion diagnostic (CDx) tests for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have been approved. In our institute, the CDx test for EGFR‐TKIs was changed from the Therascreen test (Therasc…
View article: Feasibility of next‐generation sequencing test for patients with advanced <scp>NSCLC</scp> in clinical practice
Feasibility of next‐generation sequencing test for patients with advanced <span>NSCLC</span> in clinical practice Open
Background The usefulness of the Oncomine Dx Target test (Oncomine Dx), a next‐generation sequencing (NGS) test, has already been proven in clinical trials. However, NGS requires high‐quality tumor samples and takes a long time to generate…
View article: Factors Influencing Decision-making in Relation to the Administration of Durvalumab After Chemoradiotherapy (TOPGAN2020-01)
Factors Influencing Decision-making in Relation to the Administration of Durvalumab After Chemoradiotherapy (TOPGAN2020-01) Open
目的．局所進行非小細胞肺癌患者に対しデュルバルマブが用いられるようになったが，どの程度非投与患者がいるのか明確でなく，投与割合を調査し，投与回避理由を調査した．研究計画．肺癌治療専門医がいる12施設のデータを後方視的に評価した．2018年5月から2019年12月に治療された局所進行非小細胞肺癌患者を対象とした．デュルバルマブの投与群と非投与群で患者背景を比較し，非投与理由を質問票で確認した．結果．199人が化学放射線療法を施行され，169人（84.9%）にデュルバルマブが投…
View article: Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases
Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases Open
Background The efficacy of anti‐programmed cell death‐1/ligand 1 antibody monotherapy (anti‐PD‐1/PD‐L1 monotherapy) in patients with active brain metastases (BMs) is not established. Here, we aimed to evaluate the efficacy of anti‐PD‐1/PD‐…
View article: Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors Open
View article: Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-program cell death-1/ligand 1 inhibitors
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-program cell death-1/ligand 1 inhibitors Open
Background: Dissociated responses (DR) are phenomena in which some tumors shrink, whereas others progress during treatment of patients with cancer. The purpose of the present study was to evaluate the frequency and prognosis of DR in non-s…
View article: Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients
Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients Open
Continuous decrease of plasma VEGF-A levels during treatment may be associated with the efficacy of chemo-PD1.
View article: Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer
Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer Open
STK11/LKB1 expression, as measured by immunohistochemistry, could be a useful biomarker associated with the efficacy of pembrolizumab monotherapy for patients with NSCLC and a TPS ≥50%.
View article: Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-program cell death-1/ligand 1 inhibitors
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-program cell death-1/ligand 1 inhibitors Open
Background: Dissociated responses (DR) are phenomena in which some tumors shrink, whereas others progress during treatment of patients with cancer. The purpose of the present study was to evaluate the frequency and prognosis of DR in non-s…
View article: Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer
Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer Open
A high pre-treatment NLR was associated with significantly short progression-free and overall survival in previously untreated patients with NSCLC with high expression of programmed cell-death ligand 1 treated with pembrolizumab monotherap…
View article: Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-program cell death-1/ligand 1 inhibitors
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-program cell death-1/ligand 1 inhibitors Open
Background Dissociated responses (DR) are phenomena in which some tumors shrink, whereas others progress during treatment of patients with cancer. The purpose of the present study was to evaluate the frequency and prognosis of DR in non-sm…
View article: Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer
Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer Open
TTF-1 expression in NSCLC might correlate with irTD and anti-PD-1 treatment efficacy.
View article: Acute pericarditis and mediastinal lymph node abscess developing after endobronchial ultrasound guided transbronchial needle aspiration
Acute pericarditis and mediastinal lymph node abscess developing after endobronchial ultrasound guided transbronchial needle aspiration Open
A 27-year-old man was diagnosed with inflammatory myofibroblastic tumor, and multiple lymph node and subcutaneous metastases. After several administrations of anti-tumor therapy, he underwent mediastinal lymph node biopsy using endobronchi…
View article: Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment
Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment Open